Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth

Share this content:
Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
Although cancer is one of the main causes of death in diabetic patients, few reports describe the anticancer effects of incretin. Here, we examined the effect of the incretin drug exendin (Ex)-4, a GLP-1 receptor (GLP-1R) agonist, on prostate cancer. In human prostate cancer tissue obtained from patients after they had undergone radical prostatectomy, GLP-1R expression colocalized with P504S, a marker of prostate cancer.
READ FULL ARTICLE From Diabetesjournals
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters